Stiefel forges deal to acquire Barrier Therapeutics

Stiefel Laboratories is buying Barrier Therapeutics--a developer of dermatology products--in a deal valued at $148 million. Stiefel is paying $4.15 a share for the company. In exchange, Stiefel gets three products on the market and a pipeline of experimental therapies.

"This acquisition demonstrates our continued commitment to advancing the field of therapeutic dermatology," says CEO Charles W. Stiefel. "We are very impressed with Barrier Therapeutics' innovative products and pipeline. This strategic move will further expand our oral and topical product portfolio in development and increase our sales of novel treatments for skin conditions."

- see Stiefel's release
- read the report from the South Florida Business Journal

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.